GABRIEL DIAZ: Open Payments
NPI 1124492798 · WASHINGTON, DC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,029 in 102 payments from 17 companies in 2025. Trend: 2023 $2,992 · 2024 $3,231 · 2025 $4,029
Food & beverage: $3,945Education: $84
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 24 | $1,157 |
| ABBVIE INC. | 22 | $576 |
| Janssen Scientific Affairs, LLC | 4 | $449 |
| GENZYME CORPORATION | 8 | $315 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 7 | $307 |
| PFIZER INC. | 8 | $291 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $208 |
| Phathom Pharmaceuticals, Inc. | 6 | $193 |
| Alexion Pharmaceuticals, Inc. | 1 | $126 |
| Madrigal Pharmaceuticals | 3 | $92 |
Products named: TREMFYA, DUPIXENT, XIFAXAN, ENTYVIO, CREON, VOQUEZNA, VELSIPITY, RINVOQ.
Industry payments across DC — which companies pay providers there.
